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Abstract
Background: Contrast-enhanced cardiac magnetic resonance (CMR) is pivotal for evaluating chronic myocardial
infarction (CMI). Concerns about safety of gadolinium-based contrast agents favour dose reduction. We assessed
image quality of scar tissue in CMRs performed with different doses of gadobutrol in CMI patients.
Methods: Informed consent was waived for this Ethics Committee-approved single-centre retrospective study.
Consecutive contrast-enhanced CMRs from CMI patients were retrospectively analysed according to the administered
gadobutrol dose (group A, 0.10 mmol/kg; group B, 0.15 mmol/kg; group C, 0.20 mmol/kg). We calculated the signal-to-
noise ratio for scar tissue (SNRscar) and contrast-to-noise ratio between scar and either remote myocardium (CNRscar-rem)
or blood (CNRscar-blood).
Results: Of 79 CMRs from 79 patients, 22 belonged to group A, 26 to group B, and 31 to group C. The groups were
homogeneous for age, sex, left ventricular morpho-functional parameters, and percentage of scar tissue over whole
myocardium (p ≥ 0.300). SNRscar was lower in group A (46.4; 40.3–65.1) than in group B (70.1; 52.2–111.5) (p = 0.013)
and group C (72.1; 59.4–100.0) (p = 0.002), CNRscar-rem was lower in group A (62.9; 52.2–87.4) than in group B
(96.5; 73.1–152.8) (p = 0.008) and in group C (103.9; 83.9–132.0) (p = 0.001). No other significant differences
were found (p ≥ 0.335).
Conclusions: Gadobutrol at 0.10 mmol/kg provides inferior scar image quality of CMI than 0.15 and 0.20 mmol/kg;
the last two dosages seem to provide similar LGE. Thus, for CMR of CMI, 0.15 mmol/kg of gadobutrol can be suggested
instead of 0.20 mmol/kg, with no hindrance to scar visualisation. Dose reduction would not impact on diagnostic utility
of CMR examinations.
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Key points
 Late gadolinium enhancement is pivotal in assessing
chronic myocardial infarction.
 Safety issues of gadolinium-based contrast agents ad-
vocate for dose reduction.
 Gadobutrol at 0.10 mmol/kg showed lower scar
quality compared to higher doses.
 Gadobutrol at 0.15 mmol/kg provides comparable
image quality to 0.20 mmol/kg.
 Gadobutrol at 0.15 mmol/kg can be suggested for
assessing chronic myocardial infarction.
Background
Coronary heart disease is one of the main causes of mor-
bidity and mortality, especially in developed countries,
where it causes around 20% of all deaths [1]. The most
common presentation of coronary heart disease is myo-
cardial infarction, which is defined as the occurrence of
necrosis in the setting of myocardial ischaemia[2].
Contrast-enhanced cardiac magnetic resonance (CMR)
is a multi-parametric, multi-planar imaging technique,
which represents the current non-invasive standard of
care for assessing cardiac volumes, function and tissue
characterisation through late gadolinium enhancement
(LGE) [3, 4]. The importance of LGE may be found,
among other reasons, in its prognostic potential [5]. Given
its capability to monitor cardiac conditions, contrast-
enhanced CMR may be useful in the evaluation of patients
with chronic myocardial infarction, especially when the
latter is transmural and of greater clinical relevance [6, 7].
Moreover, automatic scar quantification is growing in
popularity due to the increase in numbers of examinations
and the development of increasingly more reliable
methods [8]. Scar recognition is most often based on
image characteristics of the scarred area, such as signal-
(SNR) and contrast-to-noise ratio (CNR) [9].
However, especially in the latest years, concerns about
the safety of gadolinium-based contrast agents (GBCA)
have arisen. In addition to the well-known issue of
nephrogenic systemic fibrosis [10], gadolinium deposits
of yet unknown clinical relevance have been shown in
the brain of patients, adults and children, who under-
went repeated GBCA-enhanced magnetic resonance ex-
aminations [11, 12]. This led to a growing attention
concerning the possibility to reduce GBCA doses in such
examinations, provided that scar quality is not hindered.
Patients with chronic myocardial infarction hence rep-
resent a population where GBCA dose reduction would
lead to a lower chance of contrast-related adverse events.
At present, GBCA doses used in these patients are vari-
able among countries and centres, usually between 0.1
(single dose) and 0.2 (double dose) mmol/kg [13]. While
in some countries, such as Japan, the single dose is
recommended, in most cases there are no specific indi-
cations [14]. All doses seem to provide diagnostic quality
to examinations, albeit a reduction in scar visualisation
corresponding to a lower contrast dosage might, for in-
stance, hinder post-processing applications.
The purpose of our study was to analyse image quality
of the scar tissue in CMR examinations performed with
different GBCA doses in patients with chronic trans-
mural myocardial infarction, to investigate the impact of
gadolinium dose variation on the visibility of myocardial
LGE quantified as SNR and CNR.
Methods
Ethical statement and study design
The local Ethics Committee approved this study (Ethics
Committee of IRCCS Ospedale San Raffaele; protocol code
“Cardioretro Ricerca Spontanea”; approved on September 14,
2017, and amended on July 18, 2019). This study was sup-
ported by local research funds of IRCCS Policlinico San
Donato, a clinical research hospital partially funded by the
Italian Ministry of Health. This research received no specific
grant from funding agencies in the public, commercial, or
non-profit sector. Due to the retrospective nature of this
study, specific informed consent was waived.
Study population
All patients who had undergone a contrast-enhanced
CMR examination with administration of gadobutrol
(Gadovist, Bayer Healthcare, Leverkusen, Germany), at
our institution between March 2014 (the introduction of
our newer magnetic resonance unit) and May 2018, and
who were diagnosed with chronic myocardial infraction
from clinical findings and CMR, were included in our
study. Exclusion criteria were the presence of oedema,
indicating acute phase of infarction, presence of relevant
artefacts which rendered differentiation of the myocar-
dial scar difficult, and non-transmural, thin infarcts
which were either only subendocardial (≤ 50% of wall
thickness) or too small (scar ≤ 10% of the myocardium),
as such conditions do not allow the calculation of SNR
and CNR of the scarred region [15]. Moreover, in pa-
tients with subendocardial infarction, image contrast
may vary according to acquisition timing, and thus this
may provide data that are not compatible with those of
transmural scars [16].
Patients were then divided into three subgroups, de-
pending on the contrast dose administered during their
CMR: the first group (A) received 0.10 mmol/kg, the
second (B) 0.15 mmol/kg, and the third (C) 0.20 mmol/
kg. These different doses were mainly due to choices of
the physicians in charge of the examination during the
study period, not related to a specific patient’s condition.
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Image acquisition
All subjects were imaged using one 1.5-T whole-body
magnetic resonance unit (Magnetom Aera, Siemens
Healthineers, Erlangen, Germany) with 45 mT/m gradi-
ent power and an 18-channel surface phased-array coil.
The examined patient was lying supine and the coil was
placed over the thorax. All images were acquired with
breath-holding and ECG gating.
The imaging protocol of all patients included cine and
LGE sequences.
Cine images were acquired in multiple short- and
long-axis planes using an ECG-triggered bright-blood
steady-state free-precession pulse sequence.
LGE images were acquired after intravenous adminis-
tration of 0.10, 0.15, or 0.20 mmol/kg of gadobutrol
(Gadovist, Bayer Healthcare, Leverkusen, Germany) and
were performed using a 2D segmented inversion-
recovery fast gradient-echo sequence covering the entire
left ventricle. Earlier exams utilised higher-contrast
doses, which were then lowered over time. Nevertheless,
the sequence for LGE imaging remained the same. The
time of echo was 3.33 ms, while the time of repetition
was adapted to patients’ heart rates, and inversion time
was progressively modified from 260 to 330 ms, to
blacken cardiac muscle; flip angle was 25°, slice thickness
8 mm, and pixel size 3.6 mm2. LGE images were recon-
structed using magnitude reconstruction. From the R
wave of the electrocardiogram, a delay period was used
to ensure that image acquisition occurred in mid-
diastole, when the heart is relatively motionless, there-
fore reducing motion artefacts. Data were acquired every
other heartbeat, although in tachycardic patients data
were acquired every third heartbeat, while in bradycardic
patients and in patients with difficulties in breath hold-
ing acquisition was performed every heartbeat. Timing
between contrast administration and acquisition of de-
layed enhancement scans was tailored to the contrast
dose that was utilised in each case, according to litera-
ture recommendations [14].
Image analysis
Image analysis was performed using QMass 7.6 (Medis
Medical Imaging Systems, Leiden, The Netherlands). The
epicardial contour of the left ventricle was manually traced
for all short-axis slices at end-diastolic and end-systolic
phases in cine sequences. Afterwards, a blood-
thresholding technique (Mass-K mode) was applied to
automatically segment myocardium and blood pool. The
software then calculated end-diastolic and end-systolic
volumes, both indexed and non-indexed to body surface
area, myocardial mass, stroke volume, and ejection
fraction.
For LGE quantification, manual segmentation of endo-
cardium and epicardium of the left ventricle was
performed in inversion recovery sequences after contrast
agent injection. Then the software automatically de-
tected the myocardial scar as being 6 standard deviations
above average myocardial intensity [17]. Manual correc-
tions were made when the software erroneously detected
additional scarred areas, or when it failed to properly de-
tect the scar. LGE was quantified as percentage over the
whole myocardium. Two regions of interest were auto-
matically placed in the scarred and healthy myocardium.
An example of LGE segmentation is shown in Fig. 1.
SNR and CNR were calculated using data provided by
automatic LGE quantification, namely intensities from the
two ROIs automatically placed in the scarred and healthy
myocardium, and two additional ROIs traced in the left
ventricular blood pool and in the background air. SNR
was calculated as SNR ¼ 0:655∙ signal intensity
SDbackground
according to a
study by Kaufman et al. [18], while CNR was calculated as
CNR1=2 ¼
jsignal intensity1−signal intensity2j
SDbackground
. SNR was calculated
on the scar tissue (SNRscar), while CNR was calculated be-
tween scar tissue and remote myocardium (CNRscar-rem),
and between scar tissue and blood (CNRscar-blood). Tim-
ings between contrast injection and acquisition of LGE se-
quences were also reported.
Fig. 1 Figure showing segmentation of the scarred myocardium in
a 49-year-old male patient. Scarred myocardium is shown in red and
is automatically segmented at 6 standard deviations above average
signal intensity. Regions of interest placement is also depicted: those
in the scarred (pink) and healthy (orange) myocardium are automatically
placed during scar segmentation, while the ones in the blood pool
(yellow) and air (blue) are manually placed on the same image
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Subjective image quality was also analysed, using a 4-
point Likert scale, defining score as follows: 0: non-
diagnostic; 1: diagnostic exam, sufficient quality; 2: diag-
nostic exam, good quality; 3: diagnostic exam, excellent
quality. The quality definition was based on the visual
contrast differences between blood pool signal and LGE.
Statistical analysis
Data were reported as median and interquartile range (IQR).
Differences between groups were appraised with Kruskal-
Wallis test for numerical variables, and post hoc tests when a
significant difference was appraised by Kruskal-Wallis test, or
Fisher χ2 tests for non-numerical variables.
Statistical analysis was performed with MATLAB
R2018b (Mathworks, Natick, MA, USA), and p values ≤
0.05 were considered statistically significant.
Results
Study population
Out of 124 patients who had undergone contrast-
enhanced CMR at our institution, with gadobutrol as
GBCA, 79 were included. The flowchart of exclusion is
shown in Fig. 2. Out of the 79 included patients, 22
belonged to the group being administered 0.10 mmol/kg
of gadobutrol (group A), 26 to the group being adminis-
tered 0.15 mmol/kg of gadobutrol (group B) and 31 to the
last group, which was administered 0.20 mmol/kg of gado-
butrol (group C). There were no significant differences in
either age or sex among the three groups (p ≥ 0.300).
Group demographics are summarised in Table 1.
The median acquisition time of LGE sequences was 9
min (IQR 8–13 min) for group A, 14 min (IQR 9–17
min) for group B and 17 min (IQR 14–20 min) for group
C. Acquisition time showed a significant difference (p <
0.001) among groups; in particular, it did not differ
between group A and group B (p = 0.105), but was
shorter in group B than group C (p < 0.018), and shorter
in group A than in group C (p < 0.001).
Cardiac morphology and function
Left ventricular volumetric and functional data are re-
ported in Table 1, along with myocardial scar burden
quantified as percentage of scar tissue volume over the
whole left ventricular volume. There were no significant
differences in volumetric, functional or scar data.
Image quality
Images of LGE in patients belonging to the three differ-
ent groups are shown in Fig. 3.
SNRscar was 46.4 (IQR 40.3–65.1) in group A, 70.1 (IQR
52.2–111.5) in group B, and 72.1 (IQR 59.4–100.0) in
group C. There was a significant difference in SNRscar
among groups (p = 0.002), in particular SNRscar in group
A was lower than both that of group B (p = 0.013) and
group C (p = 0.002), while there was no significant differ-
ence in SNRscar between group B and group C (p = 0.884).
CNRscar-rem was 62.9 (IQR 52.2–87.4) in group A, 96.5
(IQR 73.1–152.8) in group B, and 103.9 (IQR 83.9–
132.0) in group C. There was a significant difference in
CNRscar-rem among groups (p < 0.001), in particular
CNRscar-rem in group A was significantly lower than both
that of group B (p = 0.008) and group C (p = 0.001),
while there was no significant difference in CNRscar-rem
between group B and group C (p = 0.871).
CNRscar-blood was 25.5 (IQR 14.4–35.0) in group A,
32.7 (IQR 17.9–60.8) in group B, and 29.6 (IQR 18.2–
53.5) in group C. There were no significant differences
in CNRscar-blood among groups (p = 0.335).
Fig. 2 Study flowchart. Out of 124 initially retrieved patients, 35 were excluded due to their infarction not being transmural and 10 due to artefacts on
late gadolinium enhancement scans regardless of the size of their infarction
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Box plots of SNRscar, CNRscar-rem, and CNRscar-blood
across the three groups are depicted in Fig. 4, and data
are reported in Table 2.
Concerning subjective image quality, no exams were
non-diagnostic (Likert score 0), 7 exams displayed suffi-
cient quality (Likert score 1), 24 exams good quality
(Likert score 2), and 48 exams excellent quality (Likert
score 3). In group A, 4 exams displayed sufficient qual-
ity, 7 good quality, and 11 excellent quality. In group B,
3 exams displayed sufficient quality, 7 good quality, and
16 excellent quality. In group C, 10 exams displayed
good quality and 21 excellent quality. There were no sig-
nificant differences in subjective image quality among
groups (p = 0.250)
Discussion
The issue of GBCA dose reduction has become crucial
in the last few years [19]. Among patients who undergo
contrast-enhanced CMR, one of the main groups is rep-
resented by patients with chronic myocardial infarction,
especially when the infarct is transmural and of greater
clinical relevance [20]. In this study, we wished to ascer-
tain whether lower GBCA doses resulted in lower scar
image quality, or if there was room for dose reduction
while preserving scar visibility. Even lower GBCA doses
guarantee diagnostic quality; however, especially given
the rise of automatic post-processing methods, it may be
important to preserve the highest possible scar discern-
ment to ensure images can be utilised for such purposes.
In fact, the quantification of LGE using standard devia-
tions may be influenced by SNR and CNR, as lower SNR
and CNR may signify that background noise has a higher
impact on intrinsic signal intensity variations, and this
may lead to less accurate scar detection, for instance
using standard deviation-related systems.
Acquisition time was optimal in all groups, never ex-
ceeding 30 min as recommended by the literature [21].
Moreover, the differences in acquisition timings reflect
the recommendations to obtain adequate image contrast
according to the dose of contrast agent used [14].
Among our study groups, there were no significant dif-
ferences in demographics or volumetric or functional left
ventricle data and scar percentage over the whole myo-
cardium. This would imply that none of these variables
should have influenced the results of our research.
Concerning scar visibility, a lower SNRscar (see Table
2) in group A than in both group B and group C could
be due to the fact that a 0.10 mmol/kg GBCA dose was
not sufficient to enhance the scarred myocardium in the
same way as the two other doses, even though timing
Table 1 Demographics, left ventricular function and volume, and scar data from the three study subgroups
Group A Group B Group C p
Number 22 26 31 −
Age (years) 68 (58–71) 62 (51–72) 60 (51–68) 0.300
Males (%) 95 92 90 0.811
LV EDVi (ml/m2) 94 (75–118) 93 (73–107) 100 (80–126) 0.319
LV ESVi (ml/m2) 58 (31–77) 56 (46–74) 63 (46–87) 0.472
LV SV (ml) 66 (46–78) 69 (60–86) 70 (62–83) 0.410
LV EF (%) 38 (28–46) 38 (31–47) 37 (30–45) 0.800
LV Mi (g/m2) 89 (81–116) 91 (77–114) 92 (77–102) 0.961
LGE (%) 32.5 (21.7–38.1) 30.9 (23.0–42.4) 31.1 (25.5–44.0) 0.594
EDVi End-diastolic volume indexed to body surface area, EF Ejection fraction, ESVi End-systolic volume indexed to body surface area, LGE Percentage of scar
represented as late gadolinium enhancement over the myocardial mass, Mi Myocardial mass index, SV Stroke volume. Kruskal-Wallis test was used
Fig. 3 Inversion recovery sequences for late gadolinium enhancement performed using 0.10 (a), 0.15 (b), or 0.20 (c) mmol/kg of gadobutrol, in
male patients of 76, 54, and 49 years of age, respectively, matched for percentage infarct size
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Fig. 4 Box plots of signal-to-noise ratio of the scarred myocardium (SNRscar), contrast-to-noise ratio between infarcted and remote myocardium (CNRscar-rem), and
contrast-to-noise ratio between infarcted myocardium and blood (CNRscar-blood) in the three groups being administered 0.10 (group A), 0.15 (group B), and 0.20
(group C) mmol/kg of gadobutrol. Significant differences between groups are indicated with an asterisk (*), and red crosses (+) indicate outliers. In particular,
SNRscar was lower in group A (46.4 IQR 40.3–65.1) than in both group B (70.1 IQR 52.2–111.5, p = 0.013) and group C (72.1 IQR 59.4–100.0, p = 0.002), and
CNRscar-rem was lower in group A (62.9 IQR 52.2–87.4) than in both group B (96.5 IQR 73.1–152.8, p = 0.008) and group C (103.9 IQR 83.9–132.0, p = 0.001). There
were no other significant differences in SNRscar, CNRscar-rem, or CNRscar-blood (p ≥ 0.335)
Table 2 Image quality and differences among the three groups according to the dose of gadobutrol used for late gadolinium
enhancement
Group A Group B Group C p value (global) p value
(A versus B)
p value
(B versus C)
p value
(A versus C)
SNRinf 46.4 (40.3–65.1) 70.1 (52.2–111.5) 72.1 (59.4–100.0) 0.002* 0.013* 0.884 0.002*
CNRscar-rem 62.9 (52.2–87.4) 96.5 (73.1–152.8) 103.9 (83.9–132.0) < 0.001* 0.008* 0.871 0.001*
CNRscar-blood 25.5 (14.4–35.0) 32.7 (17.9–60.8) 29.6 (18.2–53.5) 0.335 − − −
Group A received 0.10 mmol/kg, group B 0.15 mmol/kg, and group C 0.20 mmol/kg of gadobutrol. CNRscar-blood Contrast-to-noise ratio between myocardial scar
and blood, CNRscar-rem Contrast-to-noise ratio between scarred and remote healthy myocardium, SNRinf Signal-to-noise ratio of the myocardial scar. Kruskal-Wallis
and Fisher χ2 tests were used
*Indicates statistical significance
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was appropriate for LGE (median 9 min, IQR 8–13 min)
[22]. This hypothesis is also supported by a lower
CNRscar-rem (see Table 2) in group A than in both group
B and group C. CNRscar-blood showed no differences (see
Table 2) between group A and group B, in accordance
with our hypothesis, since both the scarred myocardium
and blood are enhanced by the same contrast dose and
are still enhanced at the time of LGE acquisition.
SNRscar was not significantly different between group B
and group C, neither did CNRscar-rem and CNRscar-blood,
suggesting that image quality between the two doses of
0.15 mmol/kg and 0.20 mmol/kg of gadobutrol is
comparable.
Our results concerning SNR and CNR were not always
similar to those obtained by other authors using the
same doses of gadobutrol. At 0.10 mmol/kg, our
SNRblood was lower than that obtained for by De Cobelli
et al. [23] using gadobutrol 0.10 mmol/kg on a group of
patients with mixed pathologies exhibiting LGE. Our
CNRscar-rem was on average slightly lower than theirs but
overlapping to a certain degree due to the wide range of
distributions; conversely, our CNRscar-blood was higher.
Their method of calculating SNR was equal to ours ex-
cept for the lack of the 0.655 adjusting factor which
would indeed lower our SNR compared to theirs. Their
method of calculating CNR was equal to ours. Concern-
ing 0.15 mmol/kg, both CNRscar-rem and CNRscar-blood
were higher than those obtained by Durmus et al. [24]
utilising gadobutrol at 0.15 mmol/kg with a 15-min
delay to LGE scan. Durmus et al. used the same method
for calculating CNR as our study. However, we should
consider that our study only included transmural infarc-
tions, while these authors did not exclude patients by
scar size. Concerning the comparison of objective image
quality parameters, while studies have assessed the dif-
ferences between different contrast agents at different
doses [25, 26], to our knowledge none have yet com-
pared different gadobutrol doses.
This study has some limitations, the first being its retro-
spective design. Results refer to the specific sequence for
LGE used at our centre, and to gadobutrol. However, fast
inversion-recovery gradient-echo sequences are widely
used in clinical practice, and our timings for LGE are
aligned to recommendations [21]. On the other hand, gad-
obutrol is commonly used in CMR [13], it has a double
concentration (1.0 M) in comparison with all other vascu-
lar/interstitial GBCAs and exhibits an r1-relaxivity rela-
tively higher. However, the double molarity should not
impact on LGE findings (obtained after about 10 min after
injection), especially concerning SNR and CNRscar-rem, as
observed by Wildgruber et al. [26], while the clearance of
each single GBCA might impact on CNRscar-blood. Con-
versely, since the relatively higher relaxivity of gadobutrol
may have positively impacted objective image quality of
LGE imaging, as also reported by Schlosser et al. [27], the re-
sults obtained for gadobutrol may not be generalizable to
GBCAs with a lower relaxivity. Another potential limitation
could be posed by the variability of the placement of the re-
gions of interest in the different areas. Nevertheless, the two
regions of interest in scarred and healthy myocardium, which
were the ones that could carry more issues, were automatic-
ally placed by the scar quantification software, and the ones
in the air and the blood pool, which were hand-drawn,
brought less difficulties. One further limitation, related to the
retrospective nature of the study, is represented by the
method used for SNR and CNR calculation. In fact, with the
only availability of LGE sequences for the assessment of such
parameters, the lone viable method for SNR and CNR calcu-
lation depended on the use of ROIs placed on the desired
structures and background. However, this method has shown
to provide the highest variability on SNR in a study by Die-
trich et al. [28]. An ideal method for SNR and CNR calcula-
tion would perhaps be the one presented by Holtackers et al.
[29], who utilised subsequent acquisitions of the same se-
quence using different inversion times. Nevertheless, we uti-
lised the same sequence for all patients, thus variations in
SNR and CNR should be of a systematic nature, thus pre-
serving statistical significance of the observed differences.
In conclusion, results from our study suggest that,
while 0.10 mmol/kg of gadobutrol provides inferior scar
image quality of CMI than 0.15 and 0.20 mmol/kg, the
last two dosages seem to provide similar LGE. In view of
a global trend of standardisation and reduction of GBCA
doses, 0.15 mmol/kg of gadobutrol could be suggested
instead of 0.20 mmol/kg, with no hindrance to image
quality. Further studies should be conducted to evaluate
whether lower GBCA dosages provide a high enough
scar quality for clinical evaluations. This would pave the
way for further GBCA dose reduction which may impact
on image quality, but not on diagnostic utility of CMR
examinations.
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